Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dextroamphetamine
Drug ID BADD_D00636
Description Dextroamphetamine is the dextrorotary enantiomer of amphetamine[A2505]. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label].
Indications and Usage Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).[Label]
Marketing Status approved; illicit
ATC Code N06BA02
DrugBank ID DB01576
KEGG ID D03740
MeSH ID D003913
PubChem ID 5826
TTD Drug ID D0T3LF
NDC Product Code 68968-0215; 72162-2043; 68968-0220; 68968-0210; 68968-0205; 27808-085
UNII TZ47U051FI
Synonyms Dextroamphetamine | Dexamphetamine | Dexamfetamine | dextro-Amphetamine | dextro Amphetamine | d-Amphetamine | d Amphetamine | Dexedrine | DextroStat | Oxydess | Curban | Dextroamphetamine Sulfate | Sulfate, Dextroamphetamine | Dextro-Amphetamine Sulfate | Dextro Amphetamine Sulfate | d-Amphetamine Sulfate | d Amphetamine Sulfate
Chemical Information
Molecular Formula C9H13N
CAS Registry Number 51-64-9
SMILES CC(CC1=CC=CC=C1)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intentional self-injury19.12.01.002; 12.01.08.036--Not Available
Irritability08.01.03.011; 19.04.02.013--
Lacrimation increased06.08.02.004--
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.001530%
Livedo reticularis24.03.04.003; 23.06.05.001--Not Available
Malaise08.01.01.003--
Memory impairment19.20.01.003; 17.03.02.003--
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood altered19.04.02.007--Not Available
Mood swings19.04.03.001--Not Available
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nausea07.01.07.0010.003286%
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.0050.000990%
Paranoia19.05.01.005--Not Available
Peripheral coldness23.06.04.008; 24.04.03.006; 08.01.09.010--Not Available
Personality change19.05.01.006; 17.02.05.019--
Personality disorder19.05.02.002--Not Available
Psychomotor hyperactivity17.01.02.011; 19.11.02.003--Not Available
Rash pruritic23.03.13.030--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Rhabdomyolysis15.05.05.0020.000675%
Seizure17.12.03.001--
Skin discolouration23.03.03.005--Not Available
Sleep disorder19.02.04.001--Not Available
Social avoidant behaviour19.05.01.007--Not Available
Somnolence17.02.04.006; 19.02.05.0030.003286%
Speech disorder17.02.08.003; 22.12.03.027; 19.19.02.002--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages